Interventional Cardiology Resource Center Editorial Programs

 
 
  • What COMPASS and RE-DUAL Mean for Aspirin and Triple Therapy   Drs Cohen and O'Donoghue review new data from the COMPASS and RE-DUAL PCI trials and potential strategies for patients who need anticoagulation and antiplatelet therapy.
  • The Top Cardiology Trials of 2017 in Review   In this annual tradition, Drs Harrington and Gibson discuss their picks for the top cardiology trials of the year, covering PCSK9 inhibitors, anti-inflammatory and anthithrombotic drugs, and PCI.
  • Mandrola's Top 10 Cardiology Stories of 2017 Controversy surrounding saturated fat and sham PCI make this year's list as well as a few medical reversals and the continuing opioid crisis. What topics would you add or omit?
  • ORBITA: Sham PCI Trial Sends Stents and CardioTwitter Reeling What are the biggest misperceptions about the trial that inspired 1700+ tweets in 9 days? And why did it send US interventional cardiologists into a tizzy while their UK counterparts remained calm?
  • DAPT Dilemmas Endure While BMS Should Fade Away   Dual antiplatelet therapy duration after coronary stenting remains debatable. Drs Harrington, Batchelor, and O'Donoghue discuss some of the data from TCT and predict the demise of bare metal stents.
  • When to Stent in Stable CAD? That Is (Still) the Question   Drs Harrington, Maron, and Patel discuss the ORBITA trial, which compared coronary stenting with sham percutaneous coronary intervention for angina relief. Why did ORBITA cause so much buzz?
  • AHAHOPE-Duchenne and Help at Last The final day of AHA 2017 brought Dr Walton Shirley to tears with studies offering hope to ease the suffering she has witnessed firsthand.
  • AHATrials We Did, Trials We Should Do Dr Walton-Shirley reflects on some major studies presented at AHA 2017 and offers a further way to approach each one.
  • Revascularization in CS: Keep It Simple and Get Out of Dodge   Drs Harrington, Batchelor, and O'Donoghue discuss the implications of the TCT late-breaking CULPRIT SHOCK trial testing culprit-only vs multivessel revascularization in unstable patients in cardiogenic shock.
  • TCTSeven Reasons New Data on Watchman Are Not Persuasive PREVAIL 5-year data and a patient-level meta-analysis nudge the Watchman left atrial appendage device to meeting noninferiority, but the devil is in the details, notes Dr Mandrola.
  • AHAMandrola Previews AHA 2017 The American Heart Association Scientific Sessions begin in Anaheim November 11. Learn which updates Dr Mandrola is most looking forward to.
  • Celebrities at Conferences: A Welcome Distraction? Medical meetings often host famous speakers, but Tom Hanks's appearance at a recent cardiology conference was for entertainment purposes only.
  • Coronary Stents Humbled Yet Again in Stable CAD ORBITA, a sham-control PCI trial, found no angina benefit for stents in patients with stable CAD. Ten years after COURAGE, it's high time cardiologists treat patients, not lesions, pleads Dr Mandrola.
  • TCTWill I Feel Better? QoL Outcomes Make the Big Stage at TCT A quality-of-life substudy of a trial comparing coronary stenting and bypass surgery could herald a new era of truly patient-centered decision-making, hopes Dr Mandrola.
  • The High Cost of Public Reporting A high-risk patient needed surgery, but Dr Koka couldn't find a surgeon willing to operate on him, for fear of looking bad on publically reported outcomes data.
  • Positive Results for PFO Closure Come With Caveats Three studies give PFO closure in cryptogenic stroke a boost, but patient selection is critical, and let's not forget about direct oral anticoagulants, cautions Dr Mandrola.
  • ESC 2017: Updates in Antithrombotic Strategies   Drs Jolly and Granger discuss three trials presented at ESC 2017 that are making waves in thrombocardiology.
  • Lipid-Lowering, CV Effects of Anacetrapib REVEALed  
  • ESC 2017: Lipids and Prevention Takeaways   Dr Jolly leads a roundtable discussion on the very low LDL-C subanalysis from FOURIER, the PURE nutrition study, and REVEAL.
  • Roadmap for a First Presentation at a Major Meeting   Dr Sheila Sahni, an interventional cardiology fellow, is interviewed by Dr Melissa Walton-Shirley on managing the ins and outs of her first oral presentation at a major medical meeting.